BioSpace News Archive

AbCellera today announced that interim data from a Phase 2 clinical trial of LY-CoV555, the first antibody to emerge from AbCellera’s collaboration with Eli Lilly and Company (Lilly) to create antibody therapies for the prevention and treatment of COVID-19, shows a reduction in the rate of hospitalization in patients treated with the antibody.

Today the company launched its first software-as-a-service (SaaS) solution, MyBloodHealth®, a hospital-based telehealth anemia management program with both perioperative and comprehensive blood management options.

Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has recently entered into a global development, manufacturing and commercialization collaboration with Wigen Biomedicine, a biomedical high-tech company committed to research and development of innovative drugs and new technologies, for Wig

Willamette Surgery Center is the first ambulatory surgery center in Salem, Oregon to offer robotic-arm assisted total knee, partial knee and total hip replacements with Stryker’s Mako System.

Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United State

The Epilepsy Foundation is hosting its fourth Annual Care & Cure Benefit Gala on September 26 at 6 p.m.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced a collaboration aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH

National Health Investors, Inc. provided a business update regarding its monthly contractual rent collections, deferral update, and average occupancy from its three largest senior housing operators.

Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15 p.m. ET. The presentation will be available online via a webinar. To listen to the live webcast, please register with Singular Research at https://www.singularresearch.com/index.php/en/ A slide presentation that will be referenced during the webcast

Updated COVID-19 case projections released by PolicyLab at Children’s Hospital of Philadelphia forecast a stable or improving situation over the next four weeks for most of the counties that the model follows, including across the Midwest and Mid-Atlantic where case counts and test positivity rates had been high for some time.